| Dr Anastacio G Herrera Jr, MD | |
|
40 Grant Ln, Columbia, KY 42728-2233 | |
| (270) 384-6066 | |
| (270) 384-2057 |
| Full Name | Dr Anastacio G Herrera Jr |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Endocrinology, Diabetes & Metabolism |
| Location | 40 Grant Ln, Columbia, Kentucky |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487655213 | NPI | - | NPPES |
| 000000049321 | Other | KY | ANTHEM PROVIDER NUMBER |
| 64213127 | Medicaid | KY | |
| TWCC611169409 | Other | KY | WORKMAN'S COMP PROVIDER # |
| 611169409-00 | Other | KY | CHAMPUS PROVIDER NUMBER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | 21312 (Kentucky) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Anastacio G Herrera Jr, MD 40 Grant Ln, Columbia, KY 42728-2233 Ph: (270) 384-6066 | Dr Anastacio G Herrera Jr, MD 40 Grant Ln, Columbia, KY 42728-2233 Ph: (270) 384-6066 |
News Archive
Astute Medical, Inc. and CRG today announced that Astute recently achieved a milestone under the terms of its existing term loan agreement with CRG. Under the term loan agreement, CRG will provide up to $30 million to support the commercialization of the NephroCheck Test System.
"Beyond integration across the two diseases, the [Global Action Plan for the Prevention and Control of Pneumonia and Diarrhea (GAPPD) released by the WHO and UNICEF last week] is an opportunity to meld global and local agendas, giving national governments a comprehensive tool to determine the specific plans, investments, and partners needed to address the unique needs of their countries and achieve the greatest health impact for their citizens," PATH CEO Steve Davis writes in the Huffington Post's "Global Motherhood" blog.
In an important breakthrough scientists in the United States have cloned monkey embryos to create embryonic stem cells.
XenoPort, Inc. announced today that it plans to move arbaclofen placarbil (AP), also known as XP19986, into Phase 3 development as a potential treatment of spasticity in multiple sclerosis (MS) patients.
Old lungs are not as capable as young lungs of fighting off an infection of the bacteria that causes tuberculosis, placing seniors at a greater risk of developing TB.
› Verified 7 days ago
Dr. Charles S Giles, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 3066 Campbellsville Rd, Columbia, KY 42728 Phone: 270-384-6451 Fax: 270-384-9100 | |
Jesus C Siady, M.D. Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 198 Creekport Dr, Columbia, KY 42728 Phone: 270-250-9428 |